- Home
- WEA vs ELTX Comparison
WEA vs ELTX Comparison
Compare WEA & ELTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | WEA | ELTX |
|---|---|---|
| Founded | 2002 | 2011 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Trusts Except Educational Religious and Charitable | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 130.2M | 141.3M |
| IPO Year | N/A | N/A |
Fundamental Metrics
Financial Performance| Metric | WEA | ELTX |
|---|---|---|
| Price | $11.19 | $8.06 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 1 |
| Target Price | N/A | ★ $13.00 |
| AVG Volume (30 Days) | 46.1K | ★ 89.8K |
| Earning Date | 01-01-0001 | 11-13-2025 |
| Dividend Yield | ★ 7.87% | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $9.60 | $4.60 |
| 52 Week High | $11.29 | $12.62 |
Technical Indicators
Market Signals| Indicator | WEA | ELTX |
|---|---|---|
| Relative Strength Index (RSI) | 61.58 | 47.38 |
| Support Level | $11.11 | $7.77 |
| Resistance Level | $11.27 | $8.64 |
| Average True Range (ATR) | 0.08 | 0.34 |
| MACD | 0.03 | 0.06 |
| Stochastic Oscillator | 79.41 | 37.89 |
Price Performance
Historical ComparisonAbout WEA Western Asset Bond Fund Share of Beneficial Interest
Western Asset Premier Bond Fund is a diversified closed-end management investment company. Its investment objective is to provide current income and capital appreciation by investing in a diversified portfolio of investment-grade bonds. The Fund invests in sectors, such as financials, energy, telecommunication services, consumer discretionary, healthcare, materials, information technology, and consumer staples.
About ELTX Elicio Therapeutics Inc.
Elicio Therapeutics Inc is a clinical-stage biotechnology company pioneering the development of cancer immunotherapies for patients with limited treatment options and poor outcomes. Its proprietary Amphiphile, or AMP, platform delivers investigational immunotherapeutics directly to the brain center of the immune system the lymph nodes. Its focus is the development of cancer immunotherapies against biologically validated but hard-to-drug targets that can be activated through lymph node trafficking.